Athebio

Athebio develops the Athebody® platform, which pairs the DARPin (designed ankyrin repeat protein) scaffold with a discovery engine to generate targeted biotherapeutic candidates. The company says its candidates offer target affinity, specificity, solubility and multi-specificity.

Its stated business model centres on partnerships and technology transfer: it provides drug developers with access to the Athebody DARPin technology. The website does not name specific partners or customers.

Athebio was founded in 2019 and is headquartered in Zürich, Switzerland; the website describes it as bootstrapped. The team page lists scientists, research associates and management, and the company has an open role for a Senior Scientist – AI Lead in Zürich.

Product: Athebody® platform: DARPin-based scaffold and discovery engine for generating targeted biotherapeutic candidates for drug developers.